Related references
Note: Only part of the references are listed.Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
Su Young Jung et al.
INVESTIGATIONAL NEW DRUGS (2020)
Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer
Sarah Alexandra Schaefer et al.
FUTURE ONCOLOGY (2019)
Dro1/Ccdc80 inactivation promotes AOM/DSS-induced colorectal carcinogenesis and aggravates colitis by DSS in mice
Jessica I. Grill et al.
CARCINOGENESIS (2018)
Gamma synuclein is a novel Twist1 target that promotes TGF-β-induced cancer cell migration and invasion
Ting Shao et al.
CELL DEATH & DISEASE (2018)
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
Gwen Lomberk et al.
NATURE COMMUNICATIONS (2018)
Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Intracellular and extracellular TGF-β signaling in cancer: some recent topics
Kohei Miyazono et al.
FRONTIERS OF MEDICINE (2018)
Identification of Epithelial-Mesenchymal Transition-related Target Genes Induced by the Mutation of Smad3 Linker Phosphorylation
Sujin Park et al.
JOURNAL OF CANCER PREVENTION (2018)
A genetic roadmap of pancreatic cancer: still evolving
Faiyaz Notta et al.
GUT (2017)
Early detection of pancreatic cancer: Where are we now and where are we going?
Bin Zhou et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Loss of DRO1/CCDC80 results in obesity and promotes adipocyte differentiation
Jessica I. Grill et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
TGF-β in pancreatic cancer initiation and progression: two sides of the same coin
Wei Shen et al.
CELL AND BIOSCIENCE (2017)
The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
Sunjida Ahmed et al.
JOURNAL OF CLINICAL MEDICINE (2017)
BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia
Cora Hallas et al.
BMC CANCER (2016)
SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms
Pilar Garcia-Tobilla et al.
GENE (2016)
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer
Thi My Hien Nguyen et al.
GYNECOLOGIC ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
KIAA1324 Suppresses Gastric Cancer Progression by Inhibiting the Oncoprotein GRP78
Jin Muk Kang et al.
CANCER RESEARCH (2015)
EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Ji Yeon Son et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
A. H. Ko et al.
BRITISH JOURNAL OF CANCER (2013)
Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
Jeong-Hwan Yoon et al.
EMBO MOLECULAR MEDICINE (2013)
Tumor Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis
Angelo Ferraro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
'Cancer associated fibroblasts' - more than meets the eye
Shalom Madar et al.
TRENDS IN MOLECULAR MEDICINE (2013)
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
Daehwan Kim et al.
GENOME BIOLOGY (2013)
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
Cole Trapnell et al.
NATURE PROTOCOLS (2012)
Transcriptional repression of the tumor suppressor DRO1 by AIB1
Juan Ferragud et al.
FEBS LETTERS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen
Caiyun Liu et al.
BMC CANCER (2010)
Bidirectional Modulation of Adipogenesis by the Secreted Protein Ccdc80/DRO1/URB
Frederic Tremblay et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Davide Melisi et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Defective TGF-β signaling sensitizes human cancer cells to rapamycin
N. Gadir et al.
ONCOGENE (2008)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells
GT Bommer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Overexpression of synuclein-γ in pancreatic adenocarcinoma
ZK Li et al.
CANCER (2004)
Share Paper
